Making an IMPACT: Advancing Alzheimer’s Disease Clinical Trials Through Workforce Development and Inclusivity

Advances in Alzheimer’s disease clinical trials are accelerating rapidly, leading to new insights and disease-modifying therapies, but how does the field continue bolstering that momentum? For Dr. Rema Raman, it’s through improving inclusivity and training for early-career researchers. Recorded at the 2024 Alzheimer’s Disease & Related Dementias Research Day, Dr. Raman joins the podcast to discuss her work in research recruitment and retention, the importance of training the next generation of clinical trialists in dementia research with the IMPACT-AD program and more from her featured presentation. Guest: Rema Raman, PhD, co-director, Institute of Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD), director, section of biostatistics, section of participant recruitment & retention section, Alzheimer’s Therapeutic Research Institute, professor of neurology, University of Southern California Show Notes Watch our YouTube page for upcoming recordings of Dr. Raman’s presentation and other featured speakers at Alzheimer’s Disease & Related Dementias Research Day 2024. Learn more about Alzheimer’s Disease & Related Dementias Research Day on our website. Learn more about the Institute of Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD) on their website. Learn more about Dr. Raman at her bio on the Keck School of Medicine website. Connect with us Find transcripts and more at our website. Email Dementia Matters: [email protected] Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter. Enjoy Dementia Matters? Consider making a gift to the Dementia Matters fund through the UW Initiative to End Alzheimer’s. All donations go toward outreach and production.

What do you do if you have a family history of dementia and are experiencing symptoms, but can’t get a diagnosis? Dr. Sara Langer has dealt with just that. In the latest episode of our Voices of Research Participants series, Dr. Langer shares the obstacles she endured to receive her diagnosis of Lewy body dementia (LBD), how her background as a neurologist influenced her search for clinical care and how she turned to dementia research to find answers. She also discusses ways that the field of dementia research could improve to support those with other forms of dementia outside of Alzheimer’s disease. Guest: Sara Langer, MD, neurologist Co-host: Sarah Walter, MSc, program administrator, Alzheimer’s Clinical Trials Consortium (ACTC) and Alzheimer’s Therapeutic Research Institute (ATRI) Show Notes Learn more about Sarah Walter at her bio on the Alzheimer’s Clinical Trials Consortium website. Listen to the first episode of the Voices of Research Participants series, “From Caregiver to Research Participant: How One Woman’s Experience as a Dementia Caregiver Drew Her to Alzheimer’s Research,” on our website, Spotify, Apple Podcasts and all podcast platforms. Learn more about Lewy body dementia by watching the 2021 Dr. Daniel I. Kaufer Lecture, “Diagnosis and Management of Dementia with Lewy Bodies,” on our YouTube page. Learn more about how to get a dementia diagnosis on our website. Connect with Us Find transcripts and more at our website. Email Dementia Matters: [email protected] Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter. Enjoy Dementia Matters? Consider making a gift to the Dementia Matters fund through the UW Initiative to End Alzheimer’s. All donations go toward outreach and production.

The brain is the most complex part of the human body, controlling thought, memory, emotion, motor skills, sensory input and all the processes that regulate our bodies. How exactly does it work, and how are clinicians able to determine whether brain changes are a result of normal aging, Alzheimer’s disease, or something else? Dr. Victoria Williams joins the podcast to explain important concepts in neuropsychology, from the difference between cognition and intelligence to how memories are made, and discuss how cognitive tests work in memory clinics. Guest: Victoria Williams, PhD, neuropsychologist, UW Health, assistant professor, Department of Medicine, University of Wisconsin School of Medicine and Public Health Show Notes Are you a clinician interested in receiving continuing education (CE) credits for listening to this episode? Find credit designation information, disclosures and evaluation information on our website and on the UW–Madison Interprofessional Continuing Education Partnership (ICEP) website. The accreditation for this course expires 3/25/2025. After this date, you will no longer be able to access the course or claim credit. Learn more about the domains and structure of the brain through the National Institute of Neurological Disorders and Stroke (NINDS) website. Learn more about Dr. Williams at her bio on the University of Wisconsin Department of Medicine website. Connect with Us Find transcripts and more at our website. Email Dementia Matters: [email protected] Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter. Enjoy Dementia Matters? Consider making a gift to the Dementia Matters fund through the UW Initiative to End Alzheimer’s. All donations go toward outreach and production.

Since the COVID-19 pandemic was declared by the World Health Organization (WHO) in 2020, there have been many concerns about how cases of COVID-19 and Long COVID or Post-COVID Conditions (PCC) affect not just a person’s physical health, but their cognition as well. In this episode, Dr. Jim Jackson talks about his path into critical illness research and his dedicated focus on unraveling the impact of Long COVID on cognition. Throughout the discussion, he talks about the parallels between Long COVID and other chronic illnesses, the effects of Long COVID across different demographics, the concurrent challenges faced by older adults and more.  Guest: James “Jim” Jackson, PsyD, director of long-term outcomes, Critical Illness, Brain Dysfunction, and Survivorship (CIBS) Center, research associate professor of medicine, director of behavioral health, ICU Recovery Center, Vanderbilt University Medical Center Show Notes Learn more about Dr. Jackson’s book, Clearing the Fog: From Surviving to Thriving with Long Covid―A Practical Guide, on Goodreads. Listen to Dr. Jackson’s interview on NPR’s Fresh Air podcast, “Millions of people have long COVID brain fog — and there's a shortage of answers.” Learn more about Dr. Jackson at his bio on the Vanderbilt University website. Learn more about Long COVID or Post-COVID Conditions on the Centers for Disease Control and Prevention (CDC) website. Connect with Us Find transcripts and more at our website. Email Dementia Matters: [email protected] Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter. Enjoy Dementia Matters? Consider making a gift to the Dementia Matters fund through the UW Initiative to End Alzheimer’s. All donations go toward outreach and production.

Hearing loss affects roughly 15.5% of Americans 20 years and older. While the majority of these individuals experience mild hearing loss, the prevalence and severity of hearing loss increases with age. What does this sensory change mean for dementia risk, and can this risk be prevented through interventions like hearing aids? Dr. Frank Lin joins the podcast to discuss the relationship between hearing loss and dementia and share findings from the Aging and Cognitive Health Evaluation in Elders, or ACHIEVE, study. Guest: Frank Lin, MD, PhD, director, Cochlear Center for Hearing and Public Health, Professor of Otolaryngology, Medicine, Mental Health, and Epidemiology, Johns Hopkins University Show Notes Read more about Dr. Lin’s study, “Hearing intervention versus health education control to reduce cognitive decline in older adults with hearing loss in the USA (ACHIEVE): a multicentre, randomised controlled trial,”  in The Lancet. Learn more about the Atherosclerosis Risk in Communities (ARIC) study, mentioned at 20:01, through the National Heart, Lung, and Blood Institute and Johns Hopkins Bloomberg School of Public Health’s websites. Read more about U.S. regulations surrounding over-the-counter hearing aids, mentioned at 34:00, in “‘A New Frontier’ for Hearing Aids,” by The New York Times. Learn more about Dr. Lin at his bio on the Johns Hopkins Bloomberg School of Public Health website. Learn more about the ACHIEVE study on their webpage. Connect with us Find transcripts and more at our website. Email Dementia Matters: [email protected] Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter. Enjoy Dementia Matters? Consider making a gift to the Dementia Matters fund through the UW Initiative to End Alzheimer’s. All donations go toward outreach and production.

Caring for a loved one with cognitive decline can be challenging. While it is a labor of love, burnout is all but inevitable. In this episode kicking off our Voices of Research Participants series with co-host Sarah Walter, Cynthia Sierra touches on her personal experience with caregiver burnout as both a caregiver and research study partner for her mother, who has early-onset Alzheimer’s disease. She also shares her unique perspective on Alzheimer’s disease research as someone who started as a family caregiver. Guest: Cynthia Sierra, MS, LPC, senior project manager, UT Health San Antonio Co-host: Sarah Walter, MSc, program administrator, Alzheimer’s Clinical Trials Consortium (ACTC) and Alzheimer’s Therapeutic Research Institute (ATRI) Show Notes Learn more about Cynthia Sierra’s research at her ResearchGate profile. Learn more about Sarah Walter at her bio on the Alzheimer’s Clinical Trials Consortium website. Find resources for people with dementia and their care partners on our website. Connect with Us Find transcripts and more at our website. Email Dementia Matters: [email protected] Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter. Enjoy Dementia Matters? Consider making a gift to the Dementia Matters fund through the UW Initiative to End Alzheimer’s. All donations go toward outreach and production.

In the past few years, new therapies shown to slow the progression of Alzheimer's disease in people in the early stages of the disease have been making their way through the U.S. Food and Drug Administration’s (FDA) approval process. With these treatments now available, there are a growing number of questions surrounding who is eligible to take these medications and what processes are needed to ensure they are prescribed safely and effectively. Host Dr. Nathaniel Chin examines the guidelines for geriatricians and clinicians prescribing lecanemab and breaks down the eligibility requirements necessary to receive this treatment. Show Notes Read Eisai/Biogen’s “Prescribing Information” for Leqembi online. Read “Lecanemab: Appropriate Use Recommendations” on the National Library of Medicine website. Read the U.S. Department of Veterans Affairs’ (VA) guidelines for prescribing lecanemab, “Lecanemab-irmb (LEQEMBI) Criteria for Use August 2023,'' online. Listen to previous Dementia Matters episodes on lecanemab, including “Putting Lecanemab into Practice: A Clinician’s Perspective on the New Alzheimer’s Treatment,” “A Closer Look at the Lecanemab Clinical Trials,” and “Introducing Lecanemab, The Latest Alzheimer’s Disease Drug to Receive FDA Accelerated Approval,” on our website and all major podcast platforms. Connect with Us Find transcripts and more at our website. Email Dementia Matters: [email protected] Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter. Enjoy Dementia Matters? Consider making a gift to the Dementia Matters fund through the UW Initiative to End Alzheimer’s. All donations go toward outreach and production.

In 2017, the National Academies of Sciences, Engineering, and Medicine published a report showing promising but inconclusive evidence suggesting that interventions like cognitive training, blood pressure control and increased physical activity reduce a person’s risk for dementia, but what does the research show now? Dr. Luke Stoeckel from the National Institute on Aging (NIA) joins the podcast to share where the research on lifestyle interventions is at, why studies on these interventions are difficult to complete and more. Guest: Luke Stoeckel, PhD, program director, Mechanistic and Translational Decision Science Program, Division of Behavioral and Social Research (DBSR), NIA Show Notes Learn about the National Academies of Sciences, Engineering, and Medicine on their website. Read the 2017 National Academies’ report, “Preventing Cognitive Decline and Dementia,” for free on their website. Learn about the National Academies’ Research Priorities for Preventing and Treating Alzheimer’s Disease and Related Dementias and find upcoming workshops on their website. Find information on the 2021 National Academies workshop mentioned by Dr. Chin at 1:36 on the National Academies website. Learn more about Dr. Stoeckel in his bio on the National Institute on Aging website. Connect with Us Find transcripts and more at our website. Email Dementia Matters: [email protected] Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter. Enjoy Dementia Matters? Consider making a gift to the Dementia Matters fund through the UW Initiative to End Alzheimer’s. All donations go toward outreach and production.

In this year-end episode of Dementia Matters, we explore the vital role of philanthropy in advancing Alzheimer's disease research and care. Mr. Dave Adam serves on the board of visitors for the UW Initiative to End Alzheimer’s (IEA) and is an avid long-distance biker. In this episode, Adam shares his journey of combining his passions for biking and Alzheimer's advocacy. With personal experiences touched by dementia, Dave discusses how he used his solo biking expeditions across Canada and Australia to raise awareness and funds to support prevention and treatment strategies, improve care and benefit researchers at the University of Wisconsin–Madison seeking a cure for Alzheimer’s disease. Guest: Dave Adam, board of visitors, UW Initiative to End Alzheimer’s (IEA)  Show Notes Do you like what you are hearing and learning? Make an impact when you make a tax-deductible gift to the Dementia Matters fund of the UW Initiative to End Alzheimer’s. All donations go toward outreach and production. Learn more about UW Initiative to End Alzheimer’s (IEA) on its website. Read more about Mr. Adam’s travel and biking stories on his website. Learn more about Mr. Adam on the UW Initiative to End Alzheimer’s website. Connect with us Find transcripts and more at our website. Email Dementia Matters: [email protected] Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

Dr. Paul Seidler joins the podcast to discuss his recent study looking at the connection between molecules in green tea and tau proteins. He also discusses the impact those molecules have on preventing cognitive decline and how these findings could lead to new strategies for treating Alzheimer’s disease. Guest: Paul Seidler, PhD, assistant professor, University of Southern California Mann School of Pharmacy and Pharmaceutical Sciences Show Notes Read more about Dr. Seidler’s study, “Structure-based discovery of small molecules that disaggregate Alzheimer's disease tissue derived tau fibrils in vitro,” on the National Library of Medicine website. Read the article on the research from the National Institute on Aging (NIA), “Study of green tea and other molecules uncovers new therapeutic strategy for Alzheimer’s,” on their website. Learn more about Dr. Seidler on the University of Southern California’s website. Connect with us Find transcripts and more at our website. Email Dementia Matters: [email protected] Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.